» Articles » PMID: 39213433

Characterization of a Unique Catechol-O-methyltransferase As a Molecular Drug Target in Parasitic Filarial Nematodes

Overview
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Filarial nematodes cause severe illnesses in humans and canines including limb deformities and disfigurement, heart failure, blindness, and death, among others. There are no vaccines, and current drugs against filarial nematodes infections have only modest effects and are prone to complications.

Methodology/principal Findings: We identified a gene (herein called DiMT) encoding an S-adenosyl-L-methionine (SAM)-dependent methyltransferase with orthologs in parasite filarial worms but not in mammals. By in silico analysis, DiMT possesses catalytic sites for binding SAM and catecholamines with high affinity. We expressed and purified recombinant DiMT protein and used it as an enzyme in a series of SAM-dependent methylation assays. DiMT acted specifically as a catechol-O-methyltransferase (COMT), catalyzing catabolic methylation of dopamine, and depicted Michaelis Menten kinetics on substrate and co-substrate. Among a set of SAM-dependent methyltransferase inhibitors, we identified compounds that bound with high affinity to DiMT's catalytic sites and inhibited its enzymatic activity. By testing the efficacy of DiMT inhibitors against microfilariae of Dirofilaria immitis in culture, we identified three inhibitors with concentration- and time-dependent effect of killing D. immitis microfilariae. Importantly, RNAi silencing of a DiMT ortholog in Caenorhabditis elegans has been shown to be lethal, likely as a result of excessive accumulation of active catecholamines that inhibit worm locomotion, pharyngeal pumping and fecundity.

Conclusions/significance: Together, we have unveiled DiMT as an essential COMT that is conserved in parasitic filarial nematodes, but is significantly different from mammalian COMTs and, therefore, is a viable target for development of novel drugs against filarial nematode infections.

References
1.
Mackenzie C, Geary T . Addressing the current challenges to finding new anthelminthic drugs. Expert Rev Anti Infect Ther. 2013; 11(6):539-41. DOI: 10.1586/eri.13.49. View

2.
Raj S, Sasidharan S, Dubey V, Saudagar P . Identification of lead molecules against potential drug target protein MAPK4 from L. donovani: An in-silico approach using docking, molecular dynamics and binding free energy calculation. PLoS One. 2019; 14(8):e0221331. PMC: 6699710. DOI: 10.1371/journal.pone.0221331. View

3.
Scott M, Guerciolini R, Szumlanski C, Weinshilboum R . Mouse kidney histamine N-methyltransferase: assay conditions, biochemical properties and strain variation. Agents Actions. 1991; 32(3-4):194-202. DOI: 10.1007/BF01980873. View

4.
Wang H, Yang L, Liu M, Luo J . Protein post-translational modifications in the regulation of cancer hallmarks. Cancer Gene Ther. 2022; 30(4):529-547. DOI: 10.1038/s41417-022-00464-3. View

5.
Wang X, Hong M . Protein Kinases and Cross-talk between Post-translational Modifications in the Regulation of Drug Transporters. Mol Pharmacol. 2022; 103(1):9-20. DOI: 10.1124/molpharm.122.000604. View